A61K 51/086
The peptide being alphamsh, alpha melanocyte stimulating hormone
Official title: {the peptide being alphaMSH, alpha melanocyte stimulating hormone}
A61K51/086 (The peptide being alphamsh, alpha melanocyte stimulating hormone) appears on 20 US grants and 24 published applications in this corpus.
Search patents in A61K- Granted patents
- 20
- Published applications
- 24
- Assignees
- 16
- Inventors
- 48
- Latest grant
- 28 Mar 2023
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 0 | 1 |
| 2002 | 1 | 0 |
| 2003 | 1 | 0 |
| 2004 | 1 | 0 |
| 2005 | 0 | 0 |
| 2006 | 1 | 3 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 2 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 1 | 2 |
| 2013 | 0 | 2 |
| 2014 | 2 | 0 |
| 2015 | 2 | 4 |
| 2016 | 2 | 0 |
| 2017 | 2 | 2 |
| 2018 | 1 | 0 |
| 2019 | 3 | 2 |
| 2020 | 1 | 2 |
| 2021 | 0 | 0 |
| 2022 | 0 | 2 |
| 2023 | 1 | 1 |
By publication year. Applications have been published since 2001.
Recent patents
- Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors28 Mar 2023US 11,612,667 B2
- Fluorescent silica-based nanoparticles4 Feb 2020US 10,548,997 B2Cornell University
- Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same5 Nov 2019US 10,464,985 B2Stc. Unm
- Enhanced in vivo targeting of radiolabelled peptides with the means of enzyme inhibitors22 Oct 2019US 10,449,260 B2
- Radiolabeled alpha-melanocyte stimulating hormone hybrid peptide for melanoma targeting26 Mar 2019US 10,238,758 B2Stc. Unm
- Chelator compositions for radiometals and methods of using same31 Aug 2023US 2023/0270892 A1Provincial Health Services Authority
- Inducing favorable effects on tumor microenvironment via administration of nanoparticle compositions23 Jun 2022US 2022/0193275 A1Cornell University
- Enhanced in Vivo Targeting of Site-Specific Drugs13 Jan 2022US 2022/0008565 A1
- Enhanced in Vivo Targeting of Radiolabelled Peptides With the Means of Enzyme Inhibitors23 Apr 2020US 2020/0121813 A1
- Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same23 Apr 2020US 2020/0123216 A1Stc. Unm
Most cited
By later US patents
- Structurally determined metallo-constructs and applications22US 6,027,711 ARhomed Incorporated · 2000
- Fluorescent silica-based nanoparticles16US 9,625,456 B2Cornell University · 2017
- Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melonoma14US 6,607,709 B1The Curators of the University of Missouri · 2003
- Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melanoma12US 6,338,834 B12002
- Melanocortin metallopeptide constructs, combinatorial libraries and applications11US 7,049,398 B1Palatin Technologies, Inc. · 2006